On Monday, Propeller Health, a leading digital therapeutics company, announced a strategic investment of an undisclosed amount from McKesson Ventures, adding to the $20M funding round announced last week. We’re told that proceeds from the investment will provide further support for Propeller’s development of additional connected medicines for the treatment of chronic respiratory disease, such as injectables for severe asthma, and expansion into new therapeutic areas, which may include immunology, diabetes, migraine and other diseases with high unmet medical… This…